<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706871</url>
  </required_header>
  <id_info>
    <org_study_id>taVNS-FD-2018</org_study_id>
    <nct_id>NCT04706871</nct_id>
  </id_info>
  <brief_title>Transcutaneous Auricular Vagus Nerve Stimulation Treatment on Functional Dyspepsia</brief_title>
  <official_title>Transcutaneous Auricular Vagus Nerve Stimulation in the Treatment of Functional Dyspepsia : A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To observe the effect of the treatment of transcutaneous auricular vagus nerve&#xD;
      stimulation (taVNS) for the functional dyspepsia (FD).&#xD;
&#xD;
      Methods: We accrued 94 patients at Beijing TongRen Hospital. All treatments were&#xD;
      self-administered by the patients at home after training at the hospital. Patients completed&#xD;
      questionnaires at baseline and after 4 weeks, 8 weeks, 12 weeks. The FD Symptoms Index,&#xD;
      Functional Dyspepsia Quality of Life Scale (FDDQL), Hamilton Anxiety Scale (HAMA), Hamilton&#xD;
      Depression Scale (HAMD), and Self-Depression Rating Scale (SDS) were performed to evaluate&#xD;
      the therapeutic effects.&#xD;
&#xD;
      A difference of P &lt; 0.05 was considered statistically significant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from Baseline in the FD Symptoms Index at 16 Weeks</measure>
    <time_frame>Day 0, 4-weeks, postintervention at Week 4, postintervention at Week 12</time_frame>
    <description>FD Symptoms Index to measure the subjective symptoms of dyspepsia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from Baseline in the FDQOL at 16 Weeks</measure>
    <time_frame>Day 0, 4-weeks, postintervention at Week 4, postintervention at Week 12</time_frame>
    <description>FDQOL to measure the subjective quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in the HAMA at 16 Weeks</measure>
    <time_frame>Day 0, 4-weeks, postintervention at Week 4, postintervention at Week 12</time_frame>
    <description>HAMA to measure the subjective anxiety symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in the HAMD at 16 Weeks</measure>
    <time_frame>Day 0, 4-weeks, postintervention at Week 4, postintervention at Week 12</time_frame>
    <description>HAMD to measure the subjective depression symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in the SDS at 16 Weeks</measure>
    <time_frame>Day 0, 4-weeks, postintervention at Week 4, postintervention at Week 12</time_frame>
    <description>SDS to measure the subjective depression symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>taVNS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tnVNS group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>taVNS</intervention_name>
    <description>taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.&#xD;
The two electrodes were placed on the cymba conchae and concha around the left ear.</description>
    <arm_group_label>taVNS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tnVNS</intervention_name>
    <description>tnVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.&#xD;
The two electrodes were placed on the antihelix around the left ear.</description>
    <arm_group_label>tnVNS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Age &gt;=18 and Age &lt;=65. 2. Clinical diagnosis of functional dyspepsia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. History of depression, tumors, thyroid disease, diabetes, cardiac diseases. 2.&#xD;
             History of gastrointestinal surgery. 3. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transcutaneous auricular vagus nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

